Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing oncology disclosures can feel like lab work—dense tables, technical risk factors, and minute clinical updates. Lixte Biotechnology Holdings adds another layer of complexity with warrant structures (ticker LIXTW) and detailed trial data on its protein phosphatase 2A inhibitors. If you have ever searched "Lixte Biotechnology SEC filings explained simply" or wondered how to trace "Lixte Biotechnology insider trading Form 4 transactions," this page is built for you.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR. It then delivers plain-English takeaways—cash runway, trial milestones, dilution risk, executive stock moves—so you can understand Lixte Biotechnology SEC documents with AI instead of sifting through hundreds of pages. Need the "Lixte Biotechnology annual report 10-K simplified"? Done. Want a quick look at the "Lixte Biotechnology quarterly earnings report 10-Q filing" or a real-time alert on "Lixte Biotechnology Form 4 insider transactions real-time"? They’re one click away, complete with side-by-side financial trend graphs and keyword search within the document.
Use cases are clear: monitor "Lixte Biotechnology 8-K material events explained" to catch trial readouts as they break, compare R&D spend across quarters, or audit "Lixte Biotechnology proxy statement executive compensation" before voting. Whether you’re tracking "Lixte Biotechnology earnings report filing analysis" or flagging "Lixte Biotechnology executive stock transactions Form 4," our platform equips you with AI-powered summaries, real-time feeds, and full historical archives—turning intricate biotech filings into actionable knowledge.
Peter Stazzone, appointed Chief Financial Officer of Lixte Biotechnology Holdings, Inc., was granted options to buy 50,000 shares of common stock at an exercise price of $4.45 per share. The options vest in four equal tranches: 25% on 09/01/2025, 25% on 12/15/2025, 25% on 03/15/2026, and 25% on 06/15/2026, subject to continuous service and possible acceleration on certain events. Each option covers one share and the options expire five years after the grant date, making the exercisable common shares underlying the grant 50,000.
Peter Stazzone filed a Form 3 reporting an initial statement of beneficial ownership for Lixte Biotechnology Holdings, Inc. (symbol shown as LIXT) related to an event on 09/01/2025. The filing identifies Mr. Stazzone as an officer with the title Chief Financial Officer and indicates the form was filed by one reporting person. The Form 3 states no securities are beneficially owned by the reporting person. The filing is signed and dated 09/04/2025.
Lixte Biotechnology Holdings, Inc. (LIXTW) Form 3 shows that Felix Lourdes, identified as a Director, filed an initial statement dated 09/01/2025 but reported no securities beneficially owned in the issuer. The signature block is dated 09/04/2025. The filing confirms the director relationship but discloses zero direct or indirect holdings in the company.
Jason David Sawyer, a newly appointed director of Lixte Biotechnology Holdings, Inc. (ticker: LIXT/LIXTW), was granted options to purchase 25,000 shares on 08/15/2025. The options have an exercise price of $3.59 per share, become exercisable immediately for 50% of the grant and vest the remaining 50% in increments—12.5% on 12/31/2025 and 12.5% on the last day of each subsequent calendar quarter—subject to continuous service, and expire on 08/15/2030. The grant was made in connection with Sawyer's appointment to the company’s board. The Form 4 was signed by the reporting person on 08/18/2025.
Michael Andrew Holloway was appointed to the board of Lixte Biotechnology Holdings, Inc. and on August 15, 2025 was granted options to purchase 25,000 shares of common stock at an exercise price of $3.59 per share. The options vest 50% immediately on the effective date and the remaining 50% vests in increments of 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested. The options are exercisable beginning August 15, 2025 and expire on August 15, 2030. The Form 4 was signed by Mr. Holloway on August 18, 2025.
FAQ
What is the current stock price of Lixte Biotechnology Hldgs (LIXTW)?
